BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22, 2024 5:11 AM EDTFOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGIONÂ
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E 4 (ApoE 4)* heterozygotes or non-carriers1
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of... More
